The publication of the most consolidated results of this trial is expected soon, and together with other ongoing studies—mostly conducted in the context of R/R AML in adult patients (NCT06226571) [136]—will help to highlight the actual benefit of menin inhibitors therapy in combination with intensive chemotherapy for KMT2Ar, NUP98r, and NPM1m leukemias. Here, MEN1 is linked to acute myeloid leukemia.